Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech has renewed its property leasing framework agreements with Clone High Tech and Fukun Pharmaceutical, both subsidiaries of controlling shareholder Fosun Pharma, extending the lease of certain premises for three years from 1 January 2026 to 31 December 2028. It has also renewed its financial services agreement with Fosun Finance, another connected party, under which Fosun Finance will continue to provide depository, credit, settlement and other financial services to the group from 14 February 2026 to 31 December 2028. In addition, the company’s wholly owned unit Henlius Bioscience has signed a new promotional services agreement with Fosun Yaohong to continue promoting its oncology drug HANQUYOU in designated areas for one year from 1 January 2026 to 31 December 2026. The renewed connected transactions, all falling under Hong Kong Listing Rules Chapter 14A, remain subject to reporting, announcement and annual review requirements but are exempt from independent shareholders’ approval, underscoring Henlius’s continued operational and commercial reliance on related-party arrangements within the Fosun group while providing regulatory clarity for investors.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a Hong Kong-listed biopharmaceutical company focused on the research, development, manufacturing and commercialization of biologic drugs, including oncology products such as HANQUYOU, with a market focus on China and international markets. The group operates through multiple subsidiaries and relies on leased facilities, intra-group financial services and promotional partnerships within the Fosun ecosystem to support its operations and commercial reach.
Average Trading Volume: 1,152,685
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.98B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.